Living Cell Technologies Ltd. (AU:1AI)
ASX:1AI
Want to see AU:1AI full AI Analyst Report?
Top Page
Living Cell Technologies
(Sydney:1AI)
Select Model
Select Model
Rating:42Neutral
Price Target:
AU$0.01
â–¼(-50.00% Downside)
Action:Upgraded
Date:04/16/26
The score is driven primarily by weak financial performance (no meaningful revenue, ongoing losses, and persistent negative free cash flow), partially offset by a debt-free balance sheet and modest improvement in recent loss/cash burn. Technical indicators also remain bearish with the price below key moving averages and negative MACD, while valuation is difficult to support given negative earnings and no dividend yield data.
Positive Factors
Debt-free balance sheet
A lack of debt meaningfully reduces fixed financing costs and default risk, giving management more flexibility to fund R&D via equity or grants. Over 2–6 months this lowers cash outflows from interest and preserves runway compared with peers that carry leverage.
Negative Factors
No meaningful revenue
Sustained absence of revenue means the business is not yet commercially validated and must rely on external funding to operate. Over months this creates persistent dilution and execution risk, as there is no recurring cash inflow to underwrite development or scale operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A lack of debt meaningfully reduces fixed financing costs and default risk, giving management more flexibility to fund R&D via equity or grants. Over 2–6 months this lowers cash outflows from interest and preserves runway compared with peers that carry leverage.
Read all positive factors
Living Cell Technologies (1AI) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$20.26M
Dividend YieldN/A
Average Volume (3M)2.98M
Price to Earnings (P/E)20.0
Beta (1Y)0.14
Revenue GrowthN/A
EPS Growth25.00%
CountryAU
Employees48
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)<0.01
Shares Outstanding2,025,571,000
10 Day Avg. Volume1,972,597
30 Day Avg. Volume2,982,772
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.79
Price to Sales (P/S)0.00
P/FCF Ratio-10.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Living Cell Technologies Business Overview & Revenue Model
Company Description
Algorae Pharmaceuticals Limited, a company established in 1987 and based in Melbourne, Australia, focuses on pioneering pharmaceutical development. Known as Living Cell Technologies Limited until its rebranding in September 2023, the firm primaril...
How the Company Makes Money
null...
Living Cell Technologies Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Jun 2024 | Jun 2024 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | -557.00 | -743.00 | -49.31K |
| EBITDA | -2.04M | -1.54M | -2.10M | -2.13M | -2.38M | -1.86M |
| Net Income | -1.01M | -802.96K | -2.10M | -2.11M | -1.96M | -1.46M |
Balance Sheet | ||||||
| Total Assets | 2.00M | 2.40M | 5.49M | 6.23M | 4.27M | 1.64M |
| Cash, Cash Equivalents and Short-Term Investments | 1.88M | 2.32M | 3.11M | 6.13M | 7.24M | 1.61M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 111.25K | 169.76K | 178.45K | 449.86K | 239.26K | 265.08K |
| Stockholders Equity | 1.89M | 2.23M | 3.01M | 3.76M | 4.03M | 1.38M |
Cash Flow | ||||||
| Free Cash Flow | -702.90K | -785.25K | -1.52M | -1.99M | -2.05M | -1.46M |
| Operating Cash Flow | -702.90K | -785.25K | -1.52M | -1.99M | -2.04M | -1.46M |
| Investing Cash Flow | 1.35M | 450.00K | -277.44K | 0.00 | 39.50K | 105.86K |
| Financing Cash Flow | 179.59K | -3.00K | 523.00K | 1.85M | 4.69M | -44.54K |
Living Cell Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | AU$2.79B | -24.29 | -14.02% | ― | 1069.25% | 18.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$12.30M | -1.84 | -218.76% | ― | 76.94% | 42.95% | |
44 Neutral | AU$6.05M | -1.57 | -29.91% | ― | 82.28% | 13.33% | |
42 Neutral | AU$20.26M | 20.00 | -49.25% | ― | ― | 25.00% | |
42 Neutral | AU$3.90M | -0.41 | -179.37% | ― | ― | 24.59% | |
41 Neutral | AU$208.27M | -15.07 | -44.80% | ― | 49.03% | -232.68% |
* Healthcare Sector Average
AU:1AI
Living Cell Technologies
0.01
<0.01
10.00%
AU:CYP
Cynata Therapeutics Limited
0.02
-0.14
-90.00%
AU:MSB
Mesoblast Limited
2.17
0.60
37.78%
AU:OCC
Orthocell Ltd
0.75
-0.34
-31.02%
AU:TRP
Tissue Repair Ltd
0.10
-0.07
-42.35%
AU:CMB
Regeneus Ltd.
0.46
0.26
130.00%
Living Cell Technologies Corporate Events
Algorae Pharmaceuticals Issues New Shares Under Cleansing Notice
Jun 19, 2026
Algorae Pharmaceuticals has issued a new tranche of fully paid ordinary shares, as detailed in an Appendix 2A lodged with the ASX, and has done so without a prospectus under the small-scale offering provisions of the Corporations Act. The company ...
Algorae Pharmaceuticals Plans Placement of 2 Million New Shares
Jun 16, 2026
Algorae Pharmaceuticals has notified the ASX of a proposed issue of up to 2,000,000 ordinary fully paid shares under a new placement or similar capital-raising structure. The securities are expected to be issued on 16 June 2026, signalling an addi...
Algorae Pharmaceuticals Issues 22 Million Unquoted Performance Rights
May 25, 2026
Algorae Pharmaceuticals Limited has issued 22,000,000 unquoted performance rights under its employee incentive scheme. The new securities, which are not intended to be quoted on the ASX, are designed to reward and retain staff, potentially dilutin...
Algorae Pharmaceuticals to List 500,000 New Employee Incentive Shares on ASX
May 25, 2026
Algorae Pharmaceuticals Limited has applied for quotation of 500,000 new ordinary fully paid shares on the ASX, to be issued on 25 May 2026 under its employee incentive scheme. The move modestly expands the company’s quoted share base and un...
Algorae Strikes Torrent Deal for Phased Launch of Generics in Australia and New Zealand
May 5, 2026
Algorae Pharmaceuticals has signed a Licence Supply Agreement with Indian drugmaker Torrent Pharmaceuticals to commercialise two generic prescription molecules in Australia and New Zealand. The deal underpins a phased commercialisation strategy t...
Algorae seals exclusive Zydus licensing deal for 10 ANZ drug products
Apr 27, 2026
Algorae Pharmaceuticals has signed an exclusive commercial and licensing agreement with India’s Zydus Lifesciences for 10 injectable, oral and specialty pharmaceutical products in Australia and New Zealand. The portfolio, to be commercialise...
Algorae Pharmaceuticals Sets Investor Webinar to Outline Q2 2026 Outlook
Apr 20, 2026
Algorae Pharmaceuticals has invited shareholders and investors to an online webinar where Executive Chairman David Hainsworth will outline the company’s current priorities, operational progress and outlook for the second quarter of 2026. Sch...
Algorae Pharmaceuticals Issues New Shares and Confirms Compliance in Cleansing Notice
Apr 7, 2026
Algorae Pharmaceuticals has issued fully paid ordinary shares, as detailed in an Appendix 2A lodged with the ASX, and confirmed these securities were issued without a formal disclosure document under the fundraising provisions of the Corporations ...
Algorae Pharmaceuticals Issues 11 Million Unquoted Options Under Existing Transaction
Apr 7, 2026
Algorae Pharmaceuticals Limited has notified the market of the issue of 11 million unquoted options, exercisable at $0.014 and expiring on Dec. 1, 2029, with an issue date of April 2, 2026. These options, designated under ASX security code 1AIAT, ...
Algorae Pharmaceuticals Seeks ASX Quotation for 172.7 Million New Shares
Apr 7, 2026
Algorae Pharmaceuticals has applied for quotation on the ASX of 172,687,970 ordinary fully paid shares, with an issue date of April 2, 2026. The application, lodged as a new announcement on April 7, 2026, reflects a significant expansion of the co...
Algorae Pharmaceuticals Seeks ASX Quotation for 89 Million New Shares
Apr 7, 2026
Algorae Pharmaceuticals has applied to the ASX for quotation of 89,350,001 new fully paid ordinary shares, issued on 2 April 2026 under its existing capital management framework. The move significantly expands the company’s quoted share base...
Algorae Pharmaceuticals Plans Major Share and Option Issue
Apr 2, 2026
Algorae Pharmaceuticals has outlined plans for a new capital raising via a placement or similar issue of securities on the ASX. The company intends to issue up to 89,350,001 fully paid ordinary shares and 11,000,000 options exercisable at $0.014 e...
Algorae Pharmaceuticals Bolsters Balance Sheet with $3.99m Capital Raise
Apr 2, 2026
Algorae Pharmaceuticals has raised approximately $3.99 million before costs through the exercise of listed options and a shortfall placement to sophisticated, long-term shareholders at a discounted issue price. The funding lifts the company’...
Algorae Wins TGA Dossier Acceptance for First Generic Medicine
Apr 1, 2026
Algorae Pharmaceuticals has had its initial registration dossier accepted for evaluation by Australia’s Therapeutic Goods Administration, marking an early but important milestone in progressing its first product toward potential commercialis...
Algorae Pharmaceuticals Issues Cleansing Notice for Newly Issued Shares
Mar 27, 2026
Algorae Pharmaceuticals has issued new fully paid ordinary shares, as reflected in an Appendix 2A lodged on the ASX, and has confirmed that these securities were issued without the need for a prospectus or disclosure document under Part 6D.2 of th...
Algorae Pharmaceuticals Seeks ASX Quotation for 44 Million New Shares
Mar 27, 2026
Algorae Pharmaceuticals Limited has applied for quotation on the ASX of 44,241,067 new fully paid ordinary shares under its ticker 1AI. The new securities, issued on March 27, 2026, expand the company’s quoted share capital and may enhance i...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.